As the Breast cancer is the most frequent cancer diagnosis in women worldwide and the second most common cause of cancer death in women, the long-term survival rates are high in patients with early-stage breast cancer who receive Aromatase inhibitors and as the treatment may continue for many years being a part of maintenance therapy, the complications resulted from therapy may significantly impact patient quality of life and compliance. Therefore we made an attempt to determine the side effects of aromatase inhibitors and their management which in turn helps the patient to continue the maintenance therapy with aromatase inhibitors successfully. I believe this study will help the prescribers to identify the effective aromatase inhibitor among the three (anastrozole, letrozole and exemestane) and the adverse effects that comes with their use and their management.